MCM
ALDX icon

Moore Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Moore Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-75,000
Closed -$1.03M – 235
2018
Q3 		$1.03M Buy
+75,000
New +$608K 0.02% 227

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Moore Capital Management's ALDX Position: Q4 2018 in Review

Moore Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2018, closing a stake of 75,000 shares — an estimated $1.03M sold.

Moore Capital Management first reported a position in ALDX in Q3 2018 and held it in 1 quarter. The position peaked at $1.03M in Q3 2018. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2018.

  • Moore Capital Management reported no remaining Aldeyra Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Moore Capital Management sold 75,000 Aldeyra Therapeutics shares in Q4 2018, an estimated $1.03M.
  • Moore Capital Management first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 1 quarter.
  • Moore Capital Management's Aldeyra Therapeutics position peaked at $1.03M in Q3 2018.
  • 77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2018.

Based on Moore Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.